Skip To Main Content
Geethashri Ananda on Muck Rack

Geethashri Ananda

As seen in: Bioprocess Online, Outsourced Pharma, Cell & Gene
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Geethashri

Contact Geethashri, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

02.18.26 -- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy

|
By Geethashri Ananda, Sujatha Chilakala
| Bioprocess Online Verified
Join us for February's Bio-Expo Live, a three-day virtual event designed to empower biopharma professionals with the chance to conveniently explore the newest equipment and offerings in Upstream Bioprocessing, Downstream Bioprocessing and Bioprocess Quality, Data, and Analytical Solutions.
Open in Who Shared Issue with article?

02.17.26 -- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy

|
By Geethashri Ananda, Kelly Cybulski, Malin Kruukka
| Cell & Gene Verified
Join MasterControl for an expert panel on the future of cell and gene therapy (CGT) manufacturing. Learn how leading organizations are tackling regulatory complexity, cGMP execution, and digital transformation as CGT scales to commercialization. Gain practical strategies to embed quality at the source, harmonize global compliance, and leverage digital tools to build resilient, future-ready CGT operations. Click here to learn more.
Open in Who Shared Issue with article?

Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy Original

|
By Geethashri Ananda
| Cell & Gene Verified
By Geethashri Ananda, Ph.D., University of Pittsburgh Cell and gene therapy (CGT) has evolved from a purely experimental field into one rapidly advancing toward large-scale manufacturing and commercialization, with dozens of products already receiving regulatory approval. This transition introduces a new set of challenges that extend beyond the digitalization of manufacturing, analytical, and quality management systems.
Open in Who Shared View Duplicates (2) Issue with article?
See all 5 articles